CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
The introduction of BCR-ABL tyrosine kinase inhibitors has revolutionized the treatment of chronic myeloid leukemia (CML). A major clinical aim remains the identification and elimination of low-level disease persistence, termed “minimal residual disease”. The phenomenon of disease persistence suggests that despite targeted therapeutic approaches, BCR-ABL-independent mechanisms exist which sustain the survival of leukemic stem cells (LSCs). Although other markers of a primitive CML LSC population have been identified in the preclinical setting, only CD26 appears to offer clinical utility. Here we demonstrate consistent and selective expression of CD93 on a lin − CD34 + CD38 − CD90 + CML LSC population and show in vitro and in vivo data to suggest increased stem cell characteristics, as well as robust engraftment in patient-derived xenograft models in comparison with a CD93 − CML stem/progenitor cell population, which fails to engraft. Through bulk and single-cell analyses of selected stem cell and cell survival-specific genes, we confirmed the quiescent character and demonstrate their persistence in a population of CML patient samples who demonstrate molecular relapse on TKI withdrawal. Taken together, our results identify that CD93 is consistently and selectively expressed on a lin − CD34 + CD38 − CD90 + CML LSC population with stem cell characteristics and may be an important indicator in determining poor TKI responders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Fig. 2 CD93 expression can isolate a functional stem cell population in CML. a Analysis of the microarray, GSE47927, demonstrated a significant fold change between CP-CML LSCs and normal HSCs in genes for cell surface proteins. The table represents the most statistically significant cell surface marker genes identified. b RNA from 30 BM and PB CP-CML samples was utilized to validate the gene expression of CD93. MNC and CD34+-selected (n = 30) samples were compared with normal BM (n = 5). c CD93 protein expression was assessed by flow cytometry in lin−CD34+CD38−CD90+ populations between CML (peripheral blood [n = 22] and BM [n = 9]) and normal BM (n = 7). A statistically significant increase in percentage of CD93+ cells in CML was determined using an unpaired Student’s t test (p < 0.0001). MNC; mononuclear cells, PB; peripheral blood, BM; bone marrow.](https://figures.cochat.ai/paper-figures/fd1f4eec7a8d4f55afd8c09dd7a48bbc/cd93-is-expressed-on-chronic-myeloid-leukemia-stem-cells-and-identifies-a-figure-2.jpg)



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860
limma powers differential expression analyses for RNA-sequencing and microarray studies
Ritchie, M. E., Phipson, B., Wu, D., Hu, Y., Law, C. W., Shi, W., & Smyth, G. K. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv007 · Cited by 40,458
Smyth, G. K. (2004) · Statistical Applications in Genetics and Molecular Biology · doi:10.2202/1544-6115.1027 · Cited by 11,829
Graham, S. M., Jørgensen, H. G., Allan, E., Pearson, C., Alcorn, M. J., Richmond, L., & Holyoake, T. L. (2002) · Blood · doi:10.1182/blood.v99.1.319 · Cited by 1,181
Self-citationCorbin, A. S., Agarwal, A., Loriaux, M., Cortes, J., Deininger, M. W., & Druker, B. J. (2011) · Journal of Clinical Investigation · doi:10.1172/jci35721 · Cited by 765
Copland, M., Hamilton, A., Elrick, L. J., Baird, J. W., Allan, E. K., Jordanides, N., Barow, M., Mountford, J. C., & Holyoake, T. L. (2006) · Blood · doi:10.1182/blood-2005-07-2947 · Cited by 635
Self-citationBhatia, R., Holtz, M., Niu, N., Gray, R., Snyder, D. S., Sawyers, C. L., Arber, D. A., Slovak, M. L., & Forman, S. J. (2003) · Blood · doi:10.1182/blood-2002-09-2780 · Cited by 547
Holyoake, T., Jiang, X., Eaves, C., & Eaves, A. (1999) · Blood · doi:10.1182/blood.v94.6.2056 · Cited by 515
Self-citationSaito, Y., Kitamura, H., Hijikata, A., Tomizawa-Murasawa, M., Tanaka, S., Takagi, S., Uchida, N., Suzuki, N., Sone, A., Najima, Y., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000349 · Cited by 458
Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival
Hamilton, A., Helgason, G. V., Schemionek, M., Zhang, B., Myssina, S., Allan, E. K., Nicolini, F. E., Müller-Tidow, C., Bhatia, R., Brunton, V. G., et al. (2012) · Blood · doi:10.1182/blood-2010-12-326843 · Cited by 435
Self-citationData exploration, quality control and testing in single-cell qPCR-based gene expression experiments
McDavid, A., Finak, G., Chattopadyay, P. K., Dominguez, M., Lamoreaux, L., Ma, S. S., Roederer, M., & Gottardo, R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts714 · Cited by 395
Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells
Krause, D. S., Lazarides, K., von Andrian, U. H., & Van Etten, R. A. (2006) · Nature Medicine · doi:10.1038/nm1489 · Cited by 349
Jørgensen, H. G., Allan, E. K., Jordanides, N. E., Mountford, J. C., & Holyoake, T. L. (2007) · Blood · doi:10.1182/blood-2006-11-057521 · Cited by 306
Self-citationDual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells
Abraham, S. A., Hopcroft, L. E. M., Carrick, E., Drotar, M. E., Dunn, K., Williamson, A. J. K., Korfi, K., Baquero, P., Park, L. E., Scott, M. T., et al. (2016) · Nature · doi:10.1038/nature18288 · Cited by 225
Self-citationDipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia
Herrmann, H., Sadovnik, I., Cerny-Reiterer, S., Rülicke, T., Stefanzl, G., Willmann, M., Hoermann, G., Bilban, M., Blatt, K., Herndlhofer, S., et al. (2014) · Blood · doi:10.1182/blood-2013-10-536078 · Cited by 223
Self-citationClark, R. E., Polydoros, F., Apperley, J. F., Milojkovic, D., Rothwell, K., Pocock, C., Byrne, J., de Lavallade, H., Osborne, W., Robinson, L., et al. (2019) · The Lancet Haematology · doi:10.1016/s2352-3026(19)30094-8 · Cited by 195
Self-citationJärås, M., Johnels, P., Hansen, N., Ågerstam, H., Tsapogas, P., Rissler, M., Lassen, C., Olofsson, T., Bjerrum, O. W., Richter, J., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1004408107 · Cited by 185
Warfvinge, R., Geironson, L., Sommarin, M. N. E., Lang, S., Karlsson, C., Roschupkina, T., Stenke, L., Stentoft, J., Olsson-Strömberg, U., Hjorth-Hansen, H., et al. (2017) · Blood · doi:10.1182/blood-2016-07-728873 · Cited by 154
Nepomuceno, R. R., & Tenner, A. J. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.4.1929 · Cited by 151
CD93 promotes β1 integrin activation and fibronectin fibrillogenesis during tumor angiogenesis
Lugano, R., Vemuri, K., Yu, D., Bergqvist, M., Smits, A., Essand, M., Johansson, S., Dejana, E., & Dimberg, A. (2018) · Journal of Clinical Investigation · doi:10.1172/jci97459 · Cited by 149
Cramer-Morales, K., Nieborowska-Skorska, M., Scheibner, K., Padget, M., Irvine, D. A., Sliwinski, T., Haas, K., Lee, J., Geng, H., Roy, D., et al. (2013) · Blood · doi:10.1182/blood-2013-05-501072 · Cited by 145
Self-citationEpigenetic Reprogramming Sensitizes CML Stem Cells to Combined EZH2 and Tyrosine Kinase Inhibition
Scott, M. T., Korfi, K., Saffrey, P., Hopcroft, L. E. M., Kinstrie, R., Pellicano, F., Guenther, C., Gallipoli, P., Cruz, M., Dunn, K., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0263 · Cited by 144
Self-citation岩崎, 正., Liedtke, M., Gentles, A. J., & Cleary, M. L. (2015) · Cell stem cell · doi:10.1016/j.stem.2015.08.008 · Cited by 144
Anjos‐Afonso, F., Currie, E., Pálmer, H. G., Foster, K., Taussig, D. C., & Bonnet, D. A. (2013) · Cell stem cell · doi:10.1016/j.stem.2013.05.025 · Cited by 138
Copland, M., Pellicano, F., Richmond, L., Allan, E. K., Hamilton, A., Lee, F. Y., Weinmann, R. S., & Holyoake, T. L. (2007) · Blood · doi:10.1182/blood-2007-09-112573 · Cited by 131
Self-citationBocchia, M., Sicuranza, A., Abruzzese, E., Iurlo, A., Sirianni, S., Gozzini, A., Galimberti, S., Aprile, L., Martino, B., Pregno, P., et al. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00194 · Cited by 108
Gerber, J. M., Gucwa, J. L., Esopi, D., Gurel, M., Haffner, M. C., Vala, M., Nelson, W. G., Jones, R. J., & Yegnasubramanian, S. (2013) · Oncotarget · doi:10.18632/oncotarget.990 · Cited by 107
Ågerstam, H., Hansen, N., von Palffy, S., Sandén, C., Reckzeh, K., Karlsson, C., Lilljebjörn, H., Landberg, N., Askmyr, M., Högberg, C., et al. (2016) · Blood · doi:10.1182/blood-2015-11-679985 · Cited by 98
Graham, S. M., Vass, J. K., Holyoake, T. L., & Graham, G. J. (2007) · Stem Cells · doi:10.1634/stemcells.2007-0250 · Cited by 96
Self-citationIdentification of CD25 as STAT5-Dependent Growth Regulator of Leukemic Stem Cells in Ph+ CML
Sadovnik, I., Hoelbl‐Kovacic, A., Herrmann, H., Eisenwort, G., Cerny‐Reiterer, S., Warsch, W., Hoermann, G., Greiner, G., Blatt, K., Peter, B., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0767 · Cited by 74
Self-citationDPPIV (CD26) as a novel stem cell marker in Ph+ chronic myeloid leukaemia
Valent, P., Sadovnik, I., Ráčil, Z., Herrmann, H., Blatt, K., Cerny‐Reiterer, S., Eisenwort, G., Lion, T., Holyoake, T. L., & Mayer, J. (2014) · European Journal of Clinical Investigation · doi:10.1111/eci.12368 · Cited by 65
Self-citationLundell, B., McCarthy, J., Kovach, N. L., & Verfaillie, C. M. (1997) · Leukemia · doi:10.1038/sj.leu.2400653 · Cited by 57
Raspadori, D., Pacelli, P., Sicuranza, A., Abruzzese, E., Iurlo, A., Cattaneo, D., Gozzini, A., Galimberti, S., Baratè, C., Pregno, P., et al. (2019) · Cytometry Part B Clinical Cytometry · doi:10.1002/cyto.b.21764 · Cited by 45
Zhao, K., Yin, L., Zhao, D., Pan, B., Chen, W., Cao, J., Cheng, H., Li, Z., Li, D., Sang, W., et al. (2014) · PubMed · Cited by 42
Čulen, M., Borský, M., Némethová, V., Rázga, F., Šmejkal, J., Jurček, T., Dvořáková, D., Žáčková, D., Weinbergerová, B., Semerád, L., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9108 · Cited by 41
Human Long-Term Culture Initiating Cell Assay
Liu, M., Miller, C., & Eaves, C. J. (2012) · Methods in molecular biology · doi:10.1007/978-1-62703-128-8_15 · Cited by 39
Differences between normal and cml stem cells: Potential targets for clinical exploitation
Eaves, A. C., Barnett, M. J., Ponchio, L., Cashman, J., Petzer, A. L., & Eaves, C. J. (2009) · Stem Cells · doi:10.1002/stem.5530160809 · Cited by 36
Willmann, M., Sadovnik, I., Eisenwort, G., Entner, M., Bernthaler, T., Stefanzl, G., Hadzijusufovic, E., Berger, D., Herrmann, H., Hoermann, G., et al. (2017) · Experimental Hematology · doi:10.1016/j.exphem.2017.09.012 · Cited by 27
Detection of BCR-ABL in Hematological Malignancies by RT-PCR
Cross, N. C. P. (2003) · Humana Press eBooks · doi:10.1385/0-89603-341-4:25 · Cited by 19
Ikewaki, N., Yamao, H., Kulski, J. K., & Inoko, H. (2010) · Journal of Clinical Immunology · doi:10.1007/s10875-010-9426-1 · Cited by 16
Cited by
Chronic Myeloid Leukemia: A Model Disease of the Past, Present and Future
Minciacchi, V. R., Kumar, R., & Krause, D. S. (2021) · Cells · doi:10.3390/cells10010117 · Cited by 180
Cancer Stem Cells—Key Players in Tumor Relapse
Marzagalli, M., Fontana, F., Raimondi, M., & Limonta, P. (2021) · Cancers · doi:10.3390/cancers13030376 · Cited by 161
Chronic myeloid leukemia stem cells: targeting therapeutic implications
Mojtahedi, H., Yazdanpanah, N., & Rezaei, N. (2021) · Stem Cell Research & Therapy · doi:10.1186/s13287-021-02659-1 · Cited by 103
Rinaldi, I., & Winston, K. (2023) · Journal of Blood Medicine · doi:10.2147/jbm.s382090 · Cited by 128
Acute Myeloid Leukemia Stem Cells: The Challenges of Phenotypic Heterogeneity
Arnone, M., Konantz, M., Hanns, P., Stanger, A. M. P., Bertels, S., Godavarthy, P. S., Christopeit, M., & Lengerke, C. (2020) · Cancers · doi:10.3390/cancers12123742 · Cited by 87
Metadata
- Authors
- Kinstrie, R., Horne, G. A., Morrison, H., Irvine, D., Munje, C., Castañeda, E. G., Moka, H. A., Dunn, K., Cassels, J. E., Parry, N., Clarke, C. J., Scott, M. T., Clark, R. E., Holyoake, T. L., Wheadon, H., & Copland, M.
- Affiliations
- University of Glasgow (GB)
- University of Liverpool (GB)
- Corresponding author
- Copland, Mhairi
- ORCID
- Venue
- Leukemia
- Published
- 2020-01-02
- Volume
- 34
- Issue
- 6
- Pages
- 1613-1625
- ISSN
- 0887-6924 (ISSN-L)
- 1476-5551
- PMC
- PMC7272220
- OpenAlex
- W2998081307
- Cited by
- 67
- References
- 40
- Citations by year
- 2026: 3 · 2025: 9 · 2024: 10 · 2023: 9 · 2022: 12 · 2021: 20 · 2020: 4
- FWCI
- 7.10
- Type
- journal article
- Language
- en
- Update notices
- correction (2020-01-31)
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Leukemia (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Wellcome Trust (100626/Z/12/Z)
- Chief Scientist Office (CAF08/09)
- Bloodwise (11017 and 14033)
- Kay Kendall Leukaemia Fund (KKL501)
- Topics
- Health Sciences › Medicine › Hematology › Chronic Myeloid Leukemia Treatments
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Keywords
- CD93, chronic myeloid leukemia, leukemia stem cells, minimal residual disease, BCR-ABL tyrosine kinase inhibitors, quiescent stem cells, patient-derived xenografts, molecular relapse, stem cell markers
- MeSH terms
- Animals, Humans, Membrane Glycoproteins, Receptors, Complement, Biomarkers, Tumor, Neoplastic Stem Cells, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Neoplasm, Residual, Drug Resistance, Neoplasm, Protein Kinase Inhibitors, Mice, Heterografts
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.